Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 220.07M P/E - EPS this Y 13.00% Ern Qtrly Grth -
Income -74.56M Forward P/E -2.75 EPS next Y 8.10% 50D Avg Chg -12.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -9.00%
Dividend N/A Price/Book 1.42 EPS next 5Y - 52W High Chg -63.00%
Recommedations 2.00 Quick Ratio 11.87 Shares Outstanding 41.45M 52W Low Chg 40.00%
Insider Own 4.45% ROA -33.33% Shares Float 21.17M Beta -1.64
Inst Own 87.18% ROE -54.13% Shares Shorted/Prior 2.96M/1.28M Price 5.83
Gross Margin - Profit Margin - Avg. Volume 100,858 Target Price 13.00
Oper. Margin - Earnings Date - Volume 33,940 Change -2.67%
About Rallybio Corporation

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

Rallybio Corporation News
04/17/24 FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting
04/12/24 RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up
04/10/24 Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
04/10/24 J&J, Rallybio partner on drug development for rare fetal condition
04/01/24 Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting
03/12/24 Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results
02/26/24 Rallybio to Present at the TD Cowen 44th Annual Health Care Conference
02/06/24 Rallybio Announces Portfolio Prioritization and Provides Corporate Update
01/29/24 Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans?
01/04/24 Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024
12/20/23 Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
12/09/23 Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting
11/28/23 Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia
11/09/23 Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates
11/08/23 Rallybio to Present at Upcoming Investor Conferences in November
08:15 AM Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting
10/03/23 Rallybio to Present at the JonesTrading 2023 Healthcare Summit
09/03/23 Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
08/31/23 Rallybio to Present at Upcoming Investor Conferences in September
08/08/23 Rallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates
RLYB Chatroom

User Image sercin Posted - 4 hours ago

$RLYB

User Image Murd_ Posted - 13 hours ago

$RLYB Just need to cross over 2.01

User Image Cast1234 Posted - 13 hours ago

$RLYB Moving in the right direction, but some news will rocket this. I got a hunch, it's coming sooner than later.

User Image YouVSYou Posted - 21 hours ago

$RLYB folks like $??? Get in this

User Image Tshanky_ Posted - 21 hours ago

$RLYB ST sleeping on this

User Image YouVSYou Posted - 21 hours ago

$RLYB 2.05 next test 🤑

User Image RollingDollar Posted - 22 hours ago

$RLYB

User Image RollingDollar Posted - 04/30/24

$RLYB

User Image YouVSYou Posted - 04/30/24

$RLYB double bag swing

User Image YouVSYou Posted - 04/30/24

$EYPT $JNJ $RLYB

User Image YouVSYou Posted - 04/30/24

$rlyb really like this daily chart Starter added

User Image Peterale Posted - 04/30/24

$RLYB Just following Tshanky's orders 😃

User Image Peterale Posted - 04/30/24

$RLYB I've been accumulating in 78s and low 80s with a small position of 11000

User Image Tshanky_ Posted - 04/30/24

$RLYB creeping. Strong buy imo

User Image Tshanky_ Posted - 04/30/24

$RLYB beast ticker. 2 catalysts coming this Q. Partnerships with $JNJ and $EYPT

User Image Cast1234 Posted - 04/30/24

@DaBullRunner take a look at $RLYB . I can’t believe it’s trading this low, this is a rocket about to happen

User Image Cast1234 Posted - 04/29/24

$RLYB been watching this one for a couple weeks, it's time. Bought some in AH's....This looks very very ripe for the run as does $MFI $MULN $CYCC

User Image RallyRaider Posted - 04/29/24

$RLYB I LOOVE these charts, looking for 2.50s+ working with a stop here -- trading only.

User Image GreenNGold22 Posted - 04/29/24

@GreenNGold22 $RLYB

User Image sercin Posted - 04/29/24

$RLYB

User Image ZeroDark0800 Posted - 04/29/24

$RLYB 💎💎

User Image Tshanky_ Posted - 04/28/24

$CADL this used to be hidden. I was alerting this before the run! Be ahead of the crowd. (Still in btw—plenty of data coming) Hidden bangers w/ catalysts imminent $MIST NDA submitted…hear back from FDA in May $LPCN was alerting at 4 and it ran to double digits PM on soft data. Now it’s back below 5 w/ Pivotal trial topline data coming this Q $RLYB multiple catalysts coming this quarter. Ran over 3.60 on JNJ partnership news (also alerted before that run— it’s back down below 1.70. Also like ERAS, ANNX, and waiting on entry for XLO (Q3 catalyst)

User Image Tshanky_ Posted - 04/26/24

Got many tickers rocking it today. $LPCN $MIST and $RLYB lagging but three of my really confident holdings throughout the quarter and year. No doubt about it.

User Image ZeroDark0800 Posted - 04/26/24

$RLYB

User Image Mindles Posted - 04/25/24

$RLYB

User Image Evo13 Posted - 04/24/24

$RLYB

User Image Tshanky_ Posted - 04/24/24

$RLYB came all the way back. This is an entry spot. Talked to IR, and $EYPT partnership update coming this quarter

User Image sercin Posted - 04/24/24

$RLYB Many stocks are down because of the "Durable Goods Orders" month over month for March. The forecast was 2.50 and it happened to be 2.60. The dust will settle tomorrow hopefully!

User Image aah98a Posted - 04/24/24

$RLYB who is selling?

User Image AceAri Posted - 04/24/24

$RLYB J&J isn’t going to invest without getting a sneak peek of what’s to come. Adding here. This is my opinion. Please do your DD!

Analyst Ratings
JMP Securities Market Outperform Apr 19, 24
JMP Securities Market Outperform Apr 18, 24
Wedbush Outperform Apr 11, 24
JMP Securities Market Outperform Mar 13, 24
HC Wainwright & Co. Buy Mar 13, 24
JMP Securities Market Outperform Feb 7, 24
Wedbush Outperform Feb 7, 24
Jefferies Hold Feb 7, 24
HC Wainwright & Co. Buy Feb 7, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
PARMAR KUSH Director Director Mar 07 Sell 8.20 100,000 820,000 2,378,969 03/09/23
5AM Partners V, LLC 10% Owner 10% Owner Mar 07 Sell 8.20 100,000 820,000 2,378,969 03/09/23
PARMAR KUSH Director Director Jun 03 Sell 12.5 150,000 1,875,000 1,251,755 06/07/22
5AM Opportunities I, L.P. 10% Owner 10% Owner Jun 03 Sell 12.5 150,000 1,875,000 2,478,969 06/07/22
PARMAR KUSH Director Director May 23 Sell 13 100,000 1,300,000 1,302,084 05/25/22
5AM Opportunities I, L.P. 10% Owner 10% Owner May 23 Sell 13 100,000 1,300,000 2,578,640 05/25/22
Fryer Jeffrey M See Remarks See Remarks Mar 21 Buy 8.04 3,000 24,120 47,048 03/23/22
5AM Opportunities I, L.P. 10% Owner 10% Owner Feb 08 Sell 13.05 210,000 2,740,500 2,645,087 02/10/22
PARMAR KUSH Director Director Feb 08 Sell 13.05 210,000 2,740,500 1,335,637 02/10/22
Fryer Jeffrey M See Remarks See Remarks Jan 19 Buy 8.70 1,400 12,180 44,048 01/21/22
Uden Stephen See Remarks See Remarks Jul 28 Buy 9.74 10,000 97,400 719,127 01/14/22
MACKAY MARTIN Chief Executive Offi.. Chief Executive Officer Jul 28 Buy 10.38 10,000 103,800 282,609 01/12/22
Fryer Jeffrey M See Remarks See Remarks Jul 28 Buy 9.21 10,000 92,100 42,648 01/11/22